Astrum

Executive Summary

Astrum is a next-generation Contract Research Organization (CRO) headquartered in Paris, France, founded in 2016. The company combines deep scientific expertise with operational innovation to deliver clinical trials that accelerate regulatory outcomes and enhance long-term value for biotech and pharmaceutical partners. Operating at Phase 2 stage, Astrum differentiates itself by offering tailored, technology-enabled trial management services that improve efficiency and data quality. Its focus on the drug delivery segment positions it to address growing demand for specialized CRO support amid the increasing complexity of modern therapeutics. As a private company with no disclosed funding or valuation, Astrum's growth trajectory is supported by the expanding global CRO market, driven by rising R&D outsourcing. The company's emphasis on regulatory alignment and value creation makes it a potential partner for mid-stage biotechs seeking to navigate clinical development hurdles. While lacking public financial metrics, Astrum's strategic positioning in France—a hub for life sciences—provides access to talent and a robust ecosystem. With a lean structure and focus on operational excellence, the company is well-placed to capture market share from larger, less agile competitors.

Upcoming Catalysts (preview)

• Q4 2026Announcement of new client partnership with a top-20 pharma60% success
• Q1 2027Launch of a proprietary digital platform for trial management50% success
• Q2 2027Expansion into the US or UK market via a new office or acquisition40% success